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Hepatitis B virus (HBV) genotyping has become important in epidemiological and clinical diagnoses,
given the relationship between the viral genotype and the progression of disease or the appearance of
antiviral resistance. Since genotyping by sequence and phylogenetic analyses is not convenient in the
clinical setting, we evaluated InnoLipa HBV genotyping (Innogenetics, Belgium) and an HBV DNA-Chip
(bioMerieux, France) prototype assay and compared their sequencing of the gold standard S gene, using
a cohort of 275 individual patient samples. All but two samples, belonging to distant and individual
subgroups within a single genotype, were detected by InnoLipa HBV assay. Four samples with dual
infections belonging to genotypes A and G were identified only by InnoLipa HBV assay. Using an HBV
DNA-Chip assay, one sample could not be amplified due to a low viral load. Four samples were identified
as genotype C and two as genotype D by sequencing but were classified as genotype A (two samples) and
D (two samples) and as A (one sample) and G (one sample) by the DNA-Chip assay. In conclusion, the
InnoLipa HBV genotyping strip assay detected dual infections and was an easy and quick tool for
genotyping, with a sensitivity of 99.3% and a specificity of 100% compared to sequence analysis. HBV
DNA-Chip assay showed a sensitivity and specificity of 97.5 and 97.8%, respectively.
It is estimated that globally, around 350 million people
are chronic carriers of hepatitis B virus (HBV) (11). Two
treatment strategies are available for HBV infection, based
on alfa interferon treatment and the use of chain termina-
tors (like lamivudine, adefovir, and entecavir). Molecular
characterization of the virus has become increasingly impor-
tant for monitoring patients (15). Recently, a correlation
was found between the progression of the disease and spe-
cific genotypes of HBV (7, 9, 25). HBV can be classified into
eight genotypes, named A to H (1, 22). This classification is
based on the distance of the nucleotide sequence from the
viral genome of 8% or greater (16, 17). These genotypes also
have a distinct geographical distribution; while genotypes A
and D are present mostly in Europe, Russia, India, and
North Africa, genotypes B and C are more common in East
Asia and Australia. Genotypes H, F, and G are present in
Central and South America. Currently, there are several
techniques available for genotyping HBV: sequence analy-
sis, microarray (DNA-Chip) (23, 26), reverse hybridization
(18), restriction fragment length polymorphism (5), serolog-
ical assays, and genotype-specific PCR assays (6, 13). Se-
quence analysis is by definition the most accurate method,
but it is also the most labor intensive technique. Other
techniques have the disadvantage that they are based on
specific hybridization of HBV DNA, and nucleotide changes
can interfere with this process and subsequent analysis.
However, sequencing can always be used as a backup tech-
nology for discrepant results. An easy-to-use and rapid
genotyping assay might become an important, routinely used
tool for disease management in the future. In this study, we
analyzed serum samples from 275 patients and compared
the sequence analysis method with the HBV InnoLipa geno-
typing kit (Innogenetics, Gent, Belgium) and an HBV DNA-
Chip assay prototype (bioMe´rieux, Marcy-l’Etoile, France).
MATERIALS AND METHODS
Sera were collected from an outpatient group participating in a clinical trial.
Sera were stored at20°C. HBV genotypes were analyzed in baseline samples by
using sequence analysis, InnoLipa HBV genotyping strips, and HBV DNA-Chip.
HBV DNA viral load was determined as described previously (10, 11).
Line probe HBV genotyping assays. For the isolation of HBV DNA from
serum, a MagnaPure LC isolation station (Roche Applied Science, Almere, The
Netherlands) with a modified HBV-02 protocol was used, as described previously
(19, 20). An InnoLipa genotyping assay (Innogenetics, Gent, Belgium) was per-
formed essentially as described previously (18), using AmpliTaq Gold DNA
polymerase (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). The
hybridization, conjugate, and substrate steps were performed by using an Auto-
LiPA instrument (Innogenetics, Gent, Belgium) according to the manufacturer’s
instructions.
Sequence analysis. Isolation of the HBV DNA from serum was performed as
described above. A product of 806 base pairs of pre-S and a part of the S gene
were amplified with the primers ACPR (sense, 5-CCTGCTGGTGGCTCCAG
TTCCGGAACAGTA-3) and YMDD-2 (antisense, 5-ACCCCATCTTTTTGT
TTTGTTAGG-3), using a PCR protocol, as follows: 10 min at 94°C, 40 cycles
of 1 min at 94°C, 1 min at 52°C and 1 min at 72°C and a final elongation step of
10 min at 72°C, using AmpliTaq Gold polymerase. The amplicon was sequenced
with the two above-mentioned primers and an additional YMDD-1 primer
(sense, 5-TCGCTGGATGTGTCTGCGGCGTTTTAT-3). Two microliters of
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the amplicon was sequenced with the BigDye Terminator version 3.1 cycle
sequencing kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
The PCR products were precipitated with 80 l NaAc buffer (3 l 3 M NaAc [pH
4.6], 62.5 l 96% ethanol, and 14.5 l distilled water) and centrifuged for 1 h
(2,500  g at room temperature). Subsequently, the pellets were washed once
with 70% ethanol and resuspended in 20 l High Dye formamide (Applied
Biosystems). The products were separated on an ABI 373 sequencer (Applied
Biosystems), and the sequence data were analyzed using a Sequence Navigator
software sequencer (Applied Biosystems) and SeqMan (DNASTAR, Madison,
WI). Sequences of 752 base pairs and Internet reference sequences obtained
from GenBank (used for comparison, Fig. 1) of different genotypes were aligned
and phylogenetic relationships were calculated with bootstrapping resampling to
calculate the nodal confidence (n  1,000) using Clustal W (Bioedit version
7.0.1) and Treeview version 1.6.6.
HBV DNA-Chip assay. Whole-HBV genome was amplified by a duplex PCR,
which generated two products of 1.7 kb and 1.5 kb (24, 26). For amplification, 10
l of extracted HBV DNA was amplified with primers provided by the manu-
facturer (bioMe´rieux, Marcy-l’Etoile, France), using the PCR protocol, as fol-
lows: 4 min at 94°C, 40 cycles of 20 s at 93°C, 45 s at 52.5°C, and 2 min and 30 s
at 68°C, and an elongation step of 7 min at 68°C, using Fast Taq polymerase
(Roche, Almere, The Netherlands). The PCR products were labeled for 25 min
at 95°C with BioPMDAM (bioMe´rieux) and fragmented for 5 min at 95°C with
0.1 N HCl (3). Subsequently, the labeled PCR products were purified using a
QIAquick PCR purification kit (Qiagen, Germany). Samples were hybridized on
TABLE 1. Comparison of HBV genotype analysis techniques


















A 92 92c 100 0 100 92 100 3 96.8
B 26 25 96.2 0 100 25 96 0 100
C 40 39 97.5 0 100 36 90 0 100
D 109 109 100 0 100 107 98.2 2 98.2
E 3 3 100 0 100 3 100 0 100
F 2 2 100 0 100 2 100 0 100
G 3 3c 100 0 100 3 100 1 75
Total 275 273 99.3 0 100 268 97.5 6 97.8
a InnoLipa produced two negative results and four mixed-population results. Although bands were visible on the gel, no bands were visible on the blot. The samples
were classified as genotype B and C by sequence analysis.
b DNA-Chip analysis produced one negative result. This sample was classified as genotype B by sequence analysis; as the viral load was 9.28 102 copies/ml, we were
unable to amplify the viral DNA with the HBV DNA microarray PCR.
c One sample was classified as genotype G, and three samples were classified as genotype A by sequence analysis.
FIG. 1. Phylogenetic tree of all samples analyzed in this cohort (n  275) by sequence analysis.










the HBV DNA-Chip prototype and stained with streptavidin-phycoerythrin con-
jugate on a GeneChip fluidics station 400 (Affymetrix, Santa Clara, CA). The
HBV DNA-Chips were scanned on an HP Gene Array scanner (Affymetrix) and
were analyzed by using DNA-Chip evaluation software (bioMe´rieux).
RESULTS
A total of 275 serum samples were analyzed by phylogenetic
analysis (Fig. 1), InnoLipa HBV genotyping assay, and HBV
DNA-Chip analysis (Table 1).
Patients included in this study came from a wide geographic
distribution, including 38% from northwestern Europe, 12%
from Eastern Europe, 32% from the Mediterranean, 11%
from East Asia, and 6% from North America. Caucasians were
infected mainly with genotype A or D (43% and 52%, respec-
tively) and Asians with genotype B or C (40% and 58%, re-
spectively). In different areas of Europe, HBV genotypes were
distributed as follows. In northwestern Europe, we found ge-
notype prevalences as follows: A, 51%; B, 7%; C, 10%; and D,
24%. For the Mediterranean area, genotype prevalences were
as follows: A, 6%; and D, 93%; and for Eastern Europe, the
genotype prevalences were A, 94%; and D, 6%. The mean log
HBV-DNA viral loads were 9.05 copies/ml for genotype A,
8.52 for genotype B, 8.57 for genotype C, and 9.33 for genotype
D. HBV DNA levels were significantly higher in sera of pa-
tients infected with genotype D than with genotypes B and C
(P  0.003).
All but one sample (9.28  102 copies/ml) had a copy num-
ber above 1,000 copies/ml, and although the limit of detection
of both sequence analysis and InnoLipa was around 1,000
copies/ml, all samples analyzed by both methods gave a band
on agarose gel, which in our hands, has a detection limit of
around 400 copies per ml (data not shown). The InnoLipa
HBV genotyping assay was able to identify the same genotype
as the sequencing method in 99.3% of the analyzed samples.
However, in two samples, no bands were visible on an Inno-
Lipa blot (HBV DNA viral load of 4.20  109 and 1.23  109
copies/ml, respectively).
As the detection limit of an HBV DNA-Chip assay is around
5,000 copies/ml, we were not able to detect HBV DNA from
one of the samples (HBV DNA viral load of 9.28 102 copies/
ml) with the HBV microarray PCR method. The HBV DNA-
Chip assay was able to identify the genotypes in 97.5% of all
analyzed samples; one sample was negative with the PCR,
while six samples initially had a result that differed from that
obtained by sequencing. Of these six samples, four were iden-
tified as genotype C but were classified by DNA-Chip analysis
as genotypes A (two samples) or D (two samples); the other
two samples were classified by DNA-Chip analysis as geno-
types A and G but were classified as genotype D by sequence
analysis. Retesting was undertaken with four of these six sam-
ples and gave the same result as sequencing, leaving two dis-
crepant results (one genotype D and one genotype C, classified
by DNA-Chip analysis as genotypes G and D, respectively).
A perfect concordance of InnoLipa HBV genotyping assay
was found in a comparison with sequence analysis for geno-
types A, D, E, and F or G (Table 1). The InnoLipa HBV
genotyping assay can detect minor virus subpopulations of
different genotypes (Fig. 2), whereas minor populations are
more difficult to interpret by sequence analysis alone. For
genotype G, two samples were classified by both assays as
genotype G alone. One sample was classified by sequence
analysis as genotype G, whereas the InnoLipa HBV genotyping
assay could detect a dual infection of genotypes A and G. Two
samples that were classified as genotype D by sequence anal-
ysis had to be retested with an InnoLipa HBV genotyping
assay. The second time, two very light bands were visible on the
InnoLipa blot, classifying these samples as genotype D. The
FIG. 2. InnoLipa HBV genotyping strips. On the left is a reference
card supplied by the manufacturer, then seven strips with genotypes A
through G and an extra strip for a double infection of genotype A
and G.










sequence alignment of these two samples (derived from two
individual patients) with the other genotype D samples showed
that these samples belonged to a subgroup (Fig. 3). Two sam-
ples could not be classified using an InnoLipa HBV genotyping
assay: one sample which was classified by sequence analysis as
genotype B (Fig. 4) and one as genotype C (Fig. 5). This
resulted in a concordance of an InnoLipa HBV genotyping
assay and a sequence analysis of 96.2% and 97.5% for geno-
type B and C, respectively.
HBV DNA-Chip assay achieved a 100% sensitivity with
FIG. 3. Phylogenetic tree of all samples classified as genotype D by sequence analysis, including the Internet reference sequences. The two
numbers shown at the left belong to two samples that the InnoLipa HBV genotyping strip had difficulties identifying. Only the second hybridization
had two very light bands.
FIG. 4. Phylogenetic tree of all samples classified as genotype B by sequence analysis, including the Internet reference sequences. The
designation number shown at the top belongs to the sample that could not be classified with the InnoLipa HBV genotyping strip.










samples that by sequence analysis, were identified as genotypes
A, E, and F or G (Table 1). However, for genotype A, we
found a specificity of 96.8%, due to three samples which were
classified as genotype C (two samples) and D (one sample) by
sequence analysis and InnoLipa. These three samples were
analyzed twice with the HBV DNA-Chip assay, and upon re-
peating, the genotypes found by sequencing and InnoLipa
were also identified by DNA-Chip analysis. Similarly, the spec-
ificities with samples identified as genotypes D and G were,
respectively, 98.2% (two false-positive results were identified
as C by sequencing and InnoLipa) and 75% (one false-positive
result was identified as genotype D by sequencing and Inno-
Lipa). Only one sample could be retested, and the genotype
found by sequencing and InnoLipa was identified correctly
upon repetition.
An HBV DNA-Chip PCR could not amplify HBV DNA
from one sample, classified as genotype B by sequence analysis,
as the viral load was below the detection limit (9.28  102
copies/ml). This resulted in a sensitivity level for the HBV
DNA-Chip assay of 96% for genotype B. HBV DNA-Chip
assay had a lower discrimination for genotype C; the sensitivity
with samples identified as genotype C by sequence analysis was
only 90%. In total, four samples determined as genotype C by
sequence analysis could not be classified correctly with an
HBV DNA-Chip assay. Two samples were classified as geno-
type A and two samples as genotype D. After repeating the
analysis, three samples were classified correctly, whereas a
fourth sample could not be retested. Although the sensitivity
was better than that for genotype C (90.0%), the sensitivity for
genotype D was 98.2%.
DISCUSSION
In this paper, we describe the comparison of three HBV
genotyping assays. Sequence analysis was used as the gold
standard and was compared to InnoLipa HBV genotyping
assay and a prototype HBV DNA-Chip assay. Using sequenc-
ing as the gold standard implies that it can be used to deter-
mine the most abundant genotype present in the sample. How-
ever, our data demonstrate that sequence analysis is not the
method of choice to determine the presence of double infec-
tions, as the quality of the sequence data themselves and the
experience of the interpreter cannot be standardized and in-
fluence the conclusion.
Only two out of 275 samples could not be classified using
HBV InnoLipa; these samples belonged to genotypes B and C,
according to sequence analysis. Most likely, this was due to
mismatches in the probes used to anneal to these HBV se-
quences. The assay was highly sensitive (96% and 98% for
genotypes B and C, respectively, and 100% for the other ge-
notypes) and specific (100%) for all genotypes. In contrast to
sequence analysis, an advantage of the InnoLipa assay is the
ability to detect dual infections. A prototype of the HBV
DNA-Chip assay was tested during this evaluation. Apart from
the future updates of the sequence patterns that will become
available, the DNA chip used in this study represents the
current status for HBV genotyping with this technology. For
this assay, the analyses resulted in a correct classification of the
HBV genotype in 97.5% of the samples. Four out of six incor-
rectly typed samples were classified by sequence analysis as
genotype C but as genotypes A (two samples) and D (two
samples) using DNA-Chip analysis. Misclassification was the
main problem of the prototype HBV chip and may be due to
an under-representation of genotype C sequences in the align-
ment used for probe sequence design of the HBV DNA-Chip.
The other two incorrectly typed samples were classified by the
DNA-Chip as genotypes A and G, but by sequence analysis,
they were classified as genotype D. Furthermore, the HBV
DNA-Chip assay is rather labor intensive; only four samples
can be hybridized and detected simultaneously.
It is clear that genotyping HBV has a place within the diag-
FIG. 5. Phylogenetic tree of all samples classified as genotype C by sequence analysis, including the Internet reference sequences. The
designation number shown at the left belongs to the sample that could not be classified with the InnoLipa HBV genotyping strip.










nostic repertoire of the clinical laboratory. There are more and
more reports describing differences in clinical outcome of the
infection for different genotypes (14), as well as differences in
outcome related to antiviral treatment with nucleoside ana-
logues. Patients infected with genotype C or D, for instance,
have a lower response to interferon treatment compared to
those infected with genotypes A or B (9, 10). There is a rela-
tionship found between the HBV genotype and the prevalence
of hepatocellular carcinoma, as well as a prognosis for disease
outcome, which is better for genotype B compared to that of
genotype C (4, 12, 21). Understanding the relationship be-
tween the genotype and outcome of disease, as well as treat-
ment, will improve patient management in the future.
Several technologies are available for easy and rapid iden-
tification of HBV genotypes. Although sequences provide the
most correct information, the easy-to-use InnoLipa assay has
some advantages. The technology has been proven for the
typing of HCV and is easy to perform, but most interestingly,
it gives indications of double infections in a given sample.
There are reports indicating that double infections occur (2, 8),
and although this occurs in a minority of patients, this infor-
mation may be valuable in guiding treatment regimens.
DNA-Chip technology is currently not used routinely in a
clinical laboratory, although the potential is enormous. Aside
from the information relating to the HBV genotype, more
sequence patterns related to antiviral resistance or promoter
sequence variation can be located on a single chip. Even se-
quences for more viruses or for the human genome could be
made available. However, it should also be noted that an easy-
to-use assay for this technology is not yet available and that the
number of samples that may be analyzed was limited to 8 to 12
per day.
In this study, we performed an extensive evaluation of tech-
nologies currently available for HBV genotyping. For routine
use, the InnoLipa assay has several advantages, while sequenc-
ing technologies should be used to determine the few samples
not detected by this assay. Implementing this technology into
routine clinical diagnostics will definitely be of value to the
determination of the relationship between HBV genotype and
the progression of disease, disease outcome, and the response
to treatment options (like interferon or nucleoside analogues).
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